argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Well good morning, everyone. Thanks to everyone for joining us this morning. My name is Graig Suvannavejh, and I am a U.S. and European biopharma analyst at Goldman Sachs. With me today are Tim Hauwermeiren -- Van Hauwermeiren. Sorry if I butchered your name, Tim. Everyone butchers my name, so my apologies for that -- CEO of the company; and Keith Woods, who is Chief Operating Officer of the company. And so today, we're going to have a discussion on argenx. And with that said, obviously, we want to lead maybe straight off with talking with Tim, just about the successes that argenx has had. Tim cofounded the company back in 2008. We're now in 2020.
Questions & Answers
So maybe if we could just start with maybe a high-level brief perspective of kind of the vision you saw for argenx 12 years ago. And maybe
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
